Clinical Trial Update: Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety and tolerability of NOVA63035, a corticosteroid, in patients with diabetic macular edema due to diabetic retinopathy;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• NOVA63035 (corticosteroid)

Snippet

Sponsor: Santen SAS | Conditions: Diabetic Macular Edema | Phase 1 | Status: COMPLETED